Ocugen Inc

OCGN remains in a Stage 2 advancing corrective reset with the active Bullish Pivot Point confirming structural repair. The recent volume-led breakout above resistance is positive, but price is extended above the rising 9/21 EMA zone and near overhead supply. Medium-term bias stays bullish in line with Stage 2, while short-term timing is unfavorable. We defer execution and stalk for a pullback into the supported EMA zone for cleaner entry. Primary risks include failure to hold the 9/21 EMA support and a reversal at the overhead resistance band.

• ↑Pivotal-stage gene therapy programs target retinitis pigmentosa and Stargardt disease for global approvals.
• ↑Planned BLA filings in 2027 with AMD therapy launch anticipated by 2028.
• ↓Q2 EPS loss of $0.07 and Q3 estimate of $0.06 reflect ongoing unprofitability.